Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning

Melphalan 200 mg/m2 in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival

Bone Marrow Transplantation volume 51, pages 1337–1341 (2016)Cite this article

Subjects

Abstract

Data on the effectiveness and toxicity of high-dose melphalan in patients with renal impairment (RI) are lacking. We evaluated the impact of RI on outcomes of patients with multiple myeloma treated with melphalan 200 mg/m2 (Mel200) and autologous stem cell transplantation. Similar baseline characteristics were seen among 46 patients with creatinine clearance (CrCl) <60 mL/min (median 50 mL/min, range 20–59) and 103 patients with CrCl ⩾60 mL/min (median 83 mL/min, range 60–128). Patients with CrCl <60 mL/min had longer time to neutrophil (P=0.008) and platelet engraftment (P<0.001). Diarrhea, duration of total parenteral nutrition use and infection were significantly higher in the CrCl <60 mL/min group. With a median follow-up of 35 months (range 2–132) in the CrCl <60 mL/min group and 47 months (range 1–45) in the CrCl ⩾60 mL/min group, overall survival was comparable between the two groups. Median treatment-free survival was longer in the RI group (37 vs 17 months, P=0.0025). Multivariate analysis showed CrCl <60 mL/min (hazard ratio (HR) 3.5), and prior proteasome inhibitor therapy (HR 2.441) both predicted longer treatment-free survival. We consider Mel200 safe and effective in patients with CrCl between 30 and 60 mL/min.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010; 28: 4976–4984.

    Article  PubMed  Google Scholar 

  2. Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005; 23: 9219–9226.

    Article  PubMed  Google Scholar 

  3. Abbott KC, Agodoa LY . Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 2001; 56: 207–210.

    CAS  PubMed  Google Scholar 

  4. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.

    Article  CAS  PubMed  Google Scholar 

  5. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 1996; 335: 91–97.

    Article  CAS  PubMed  Google Scholar 

  6. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc 2013; 88: 360–376.

    Article  PubMed  Google Scholar 

  7. ALKERAN (melphalan) [package insert]. Aspen: St Leonards, NSW, Australia; GlaxoSmithKline: Research Triangle Park, NC, USA. Revised 31 July 2010.

  8. Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L et al. Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015; 21: 1155–1166.

    Article  PubMed  Google Scholar 

  9. Vesole DH, Tricot G, Jagannath S, Desikan KR, Siegel D, Bracy D et al. Autotransplants in multiple myeloma: what have we learned? Blood 1996; 88: 838–847.

    CAS  PubMed  Google Scholar 

  10. Nieto Y, Vaughan WP . Pharmacokinetics of high-dose chemotherapy. Bone Marrow Transplant 2004; 33: 259–269.

    Article  CAS  PubMed  Google Scholar 

  11. Samuels BL, Bitran JD . High-dose intravenous melphalan: a review. J Clin Oncol 1995; 13: 1786–1799.

    Article  CAS  PubMed  Google Scholar 

  12. Grzasko N, Morawska M, Hus M . Optimizing the treatment of patients with multiple myeloma and renal impairment. Clin Lymphoma Myeloma Leuk 2015; 15: 187–198.

    Article  PubMed  Google Scholar 

  13. Reiter E, Kalhs P, Keil F, Rabitsch W, Gisslinger H, Mayer G et al. Effect of high-dose melphalan and peripheral blood stem cell transplantation on renal function in patients with multiple myeloma and renal insufficiency: a case report and review of the literature. Ann Hematol 1999; 78: 189–191.

    Article  CAS  PubMed  Google Scholar 

  14. Tosi P, Zamagni E, Ronconi S, Benni M, Motta MR, Rizzi S et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia 2000; 14: 1310–1313.

    Article  CAS  PubMed  Google Scholar 

  15. St Bernard R, Chodirker L, Masih-khan E, Jiang H, Franke N, Kukreti V et al. Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure. Bone Marrow Transplant 2015; 50: 95–99.

    Article  CAS  PubMed  Google Scholar 

  16. Sirohi B, Powles R, Kulkarni S, Rudin C, Saso R, Rigg A et al. Glomerular filtration rate prior to high-dose melphalan 200 mg/m2 as a surrogate marker of outcome in patients with myeloma. Br J Cancer 2001; 85: 325–332.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Tricot G, Alberts DS, Johnson C, Roe DJ, Dorr RT, Bracy D et al. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res 1996; 2: 947–952.

    CAS  PubMed  Google Scholar 

  18. Carlson K . Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival. Bone Marrow Transplant 2005; 35: 985–990.

    Article  CAS  PubMed  Google Scholar 

  19. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822–829.

    Article  CAS  PubMed  Google Scholar 

  20. Knudsen LM, Nielsen B, Gimsing P, Geisler C . Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 2005; 75: 27–33.

    Article  PubMed  Google Scholar 

  21. Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J et al. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. Br J Haematol 2006; 134: 385–390.

    Article  CAS  PubMed  Google Scholar 

  22. Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A et al. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 812–816.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Bodge MN, Reddy S, Thompson MS, Savani BN . Preparative regimen dosing for hematopoietic stem cell transplantation in patients with chronic kidney disease: analysis of the literature and recommendations. Biol Blood Marrow Transplant 2014; 20: 908–919.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL, USA

    K Sweiss & S Patel

  2. Cancer Center, University of Illinois, Chicago, IL, USA

    K Sweiss, D Rondelli & P Patel

  3. Department of Pharmacy, Vanderbilt University Medical Center, Nashville, TN, USA

    K Culos

  4. Division of Hematology/Oncology, University of Illinois at Chicago, Chicago, IL, USA

    A Oh, D Rondelli & P Patel

Authors
  1. K Sweiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Culos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Rondelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K Sweiss.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sweiss, K., Patel, S., Culos, K. et al. Melphalan 200 mg/m2 in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival. Bone Marrow Transplant 51, 1337–1341 (2016). https://doi.org/10.1038/bmt.2016.136

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.136

This article is cited by

Search

Advanced search

Quick links